Laura Shawver, Director at ARS Pharmaceuticals, Inc. (SPRY), sold 50,000 shares at $11.21 ($560K) on 2025-03-06, disclosed to the SEC on 2025-03-07.
Scheduled sale ($560k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.00 | 400 | $4K | 0.8% |
| 2 | $11.21 | 49,600 | $556K | 99.2% |
| Total | $11.21 avg | 50,000 | $560K | 100% |
| Filing → |
| SPRY | SELL | 2025-01-07 | $555K | — | Filing → |
| SPRY | SELL | 2024-12-04 | $5.2M | — | Filing → |
| SPRY | SELL | 2023-09-05 | $771K | — | Filing → |